Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. GemPharmatech Co's Revenue for the
three
months ended in Jun. 2026 was ¥251.5 Mil. GemPharmatech Co's average Accounts Receivable for the
three
months ended in Jun. 2026 was ¥424.1 Mil.
Hence, GemPharmatech Co's Receivables Turnover for the
three
months ended in Jun. 2026 was 0.59.
GemPharmatech Co (SHSE:688046) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
GemPharmatech Co Receivables Turnover Related Terms
GemPharmatech Co Receivables Turnover Historical Data
* Premium members only.
The historical data trend for GemPharmatech Co's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688046 vs VRTX, REGN, RVMD: Receivables Turnover Comparison
For the Biotechnology subindustry, GemPharmatech Co's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GemPharmatech Co Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, GemPharmatech Co's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where GemPharmatech Co's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GemPharmatech Co (SHSE:688046) has a Receivables Turnover of 0.59 as of Jun. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on GemPharmatech Co and its competitors. According to the industry distribution chart, GemPharmatech Co ranks #722 out of 847 companies in the Biotechnology industry, placing it in the top 85.2%.
Is GemPharmatech Co's Receivables Turnover too high?
GemPharmatech Co's current Receivables Turnover is 0.59. The Biotechnology industry median Receivables Turnover is 5.27. GemPharmatech Co's value of 0.59 is 88.8% below this industry median. Based on the distribution chart, GemPharmatech Co ranks #722 out of 847 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, GemPharmatech Co has a GF Score™ of 89/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GemPharmatech Co's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, GemPharmatech Co ranks #722 out of 847 companies for Receivables Turnover. This places GemPharmatech Co in the lower half of its industry. The industry median Receivables Turnover is 5.27. GemPharmatech Co's value of 0.59 is 88.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.27, based on 847 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GemPharmatech Co's current Receivables Turnover of 0.59 is 88.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on GemPharmatech Co and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GemPharmatech Co's current Receivables Turnover is 0.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GemPharmatech Co stock overvalued right now?
Based on GuruFocus' analysis, GemPharmatech Co (SHSE:688046) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥19.96, compared to a current price of ¥36.00 — trading 80.4% above its estimated fair value. The current Receivables Turnover is 0.59 and 88.8% below the Biotechnology industry median of 5.27. GemPharmatech Co's overall GF Score™ is 89/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For GemPharmatech Co (SHSE:688046), the current Receivables Turnover is 0.59 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GemPharmatech Co (SHSE:688046) Overvalued in 2026?
Based on GuruFocus' analysis, GemPharmatech Co stock appears to be overvalued.
The current stock price of ¥36.00 is trading 80.4% above its estimated GF Value™ of ¥19.96.
GuruFocus considers GemPharmatech Co to be Significantly Overvalued.
Key valuation signals for SHSE:688046:
Receivables Turnover: 0.59
GF Value™: ¥19.96 vs. price of ¥36.00 (80.4% above fair value)
Industry Position: 88.8% below the Biotechnology median (#722 of 847)
No single metric tells the full story. See the SHSE:688046 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GemPharmatech Co Ltd is a provider of genetically engineered mouse models and services to preclinical research and development communities. The company develops mouse models with independent intellectual property rights based on technical platforms such as gene editing, stem cells, phenotypic analysis, efficacy analysis, and sterile animals, and carries out one-stop services such as model customization, customized breeding, and functional efficacy analysis.
89GF Score
Get the complete analysis for SHSE:688046
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688046 has been successfully added to your 
